Work

Supplementary table S1 from Low-dose Paclitaxel with Pembrolizumab Enhances Clinical and Immunologic Responses in Platinum-refractory Urothelial Carcinoma

Year: 2024

Type: supplementary-materials

Abstract: MicroRNA levels are shown in responders and non-responders at baseline, after 3 cycles, and after 6 cycles of treatment. P-values suggest there is a trend toward differences in plasma miR 20a, miR 21, miR 125, miR 181, and miR 223 between responders and nonresponders. In the urine, only baseline levels of miR 21 suggest a difference.

DOI: 10.1158/2767-9764.25288982

Authors: Rhonda L. Bitting, Janet A. Tooze, Michael Goodman, Donald C. Vile, Jessica M. Brown, Christopher Y. Thomas, Morgan Neve, Mitra Kooshki, Safoa Addo, Pierre L. Triozzi, Purnima Dubey

Language: English

Topic: Bladder and Urothelial Cancer Treatments

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4392156120

Cites:

Cited by:

Related to: 10